Attacking pathogens through their hosts

Genome Biology

Volumn 7, Issue 1, 2006, Pages

  Kellam, Paul ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; ABELSON KINASE; ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATM PROTEIN; CELL PROTEIN; CHOLESTEROL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; HISTONE DEACETYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; INDOMETACIN; INTERLEUKIN 2; MEVINOLIN; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN TYROSINE KINASE; RIBAVIRIN; SEMAPIMOD; SEOCALCITOL; SMALL INTERFERING RNA; UNINDEXED DRUG; VALPROIC ACID; VITAMIN D; VITAMIN D RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTHRITIS; CARDIOTOXICITY; CELL FUNCTION; CROHN DISEASE; DRUG ACTIVITY; DRUG TARGETING; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST CELL; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROBIAL GROWTH; NONHUMAN; REVIEW; VACCINIA; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECT; HOST PARASITE INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS; METABOLISM; PATHOGENICITY; PHYSIOLOGY;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIVIRAL AGENTS; HIV; HOST-PARASITE RELATIONS; HUMANS; MODELS, BIOLOGICAL;

EID: 32944455217     PISSN: 1474760X     EISSN: 1474760X     Source Type: Journal    
DOI: 10.1186/gb-2006-7-1-201     Document Type: Review

References (42)

1. Schmid MB: Seeing is believing: the impact of structural genomics on antimicrobial drug discovery. Nat Rev Microbiol 2004, 2:739-746.
2. De Clercq E: Strategies in the design of antiviral drugs. Nat Rev Drug Discov 2002, 1:13-25.
3. Weber J, Courvalin P: An emptying quiver: antimicrobial drugs and resistance. Emerg Infect Dis 2005, 11:791-793.
4. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: new estimates of drug development. J Health Econ 2003, 22:151-185.
5. Frank RG: New estimates of drug development costs. J Health Econ 2003, 22:325-330.
6. Mullin R: Drug development costs about $1.7 billion. Chem Eng News 2003, 81:8.
7. Weiss RA, McMichael AJ: Social and environmental risk factors in the emergence of infectious diseases. Nat Med 2004, 10:S70-S76.
8. Kellam P: Host-pathogen studies in the post-genomic era. Genome Biol 2000, I:reviews 1009.1-1009.4.
9. Jenner RG, Young RA: Insights into host responses against pathogens from transcriptional profiling. Nat Rev Microbiol 2005, 3:281-294.
10. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling M-H, Albrech J: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998, 339:1493-1499.
11. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A: Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997, 26:961-966.
12. Stellbrink HJ, van Lunzen J, Westhy M, O'Sullivan E, Schneider C, Adam A, Weitner L, Kuhlmann B, Hoffmann C, Fenske S, et al.: Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 2002, 16:1479-1487.
13. Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm A, Chahroudi A, Chavan R, Feinberg MB, Veach D, et al.: Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med 2005, 11:731-739.
14. Moses AV, Jarvis MA, Raggo C, Bell YC, Ruhl R, Luukkonen BG, Griffith DJ, Wait CL, Druker BJ, Heinrich MC, et al.: Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol 2002, 76:8383-8399.
15. Zhu H, Cong JP, Yu D, Bresnahan WA, Shenk TE: Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc Natl Acad Sci USA 2002, 99:3932-3937.
16. Jenner RG, Maillard K, Cattini N, Weiss RA, Boshoff C, Wooster R, Kellam P: Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci USA 2003, 100:10399-10404.
17. del Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C, Alegret M, Pena JM, Rodriguez-Zapata M, Alvarez-Mon M, et al.: Statins inhibit HIV-1 infection by down-regulating rho activity. J Exp Med 2004, 200:541-547.
18. Bordier BB, Marion PL, Ohashi K, Kay MA, Greenberg HB, Casey JL, Glenn JS: A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J Virol 2002, 76:10465-10472.
19. Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, Ohashi K, Meuse L, Kay MA, Casey JL, et al.: In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 2003, 112:407-414.
20. Hirsch AJ, Medigeshi GR, Meyers HL, DeFilippis V, Fruh K, Briese T, Lipkin WI, Nelson JA: The Src family kinase c-Yes is required for maturation of West Nile virus particles. J Virol 2005, 79:11943-11951.
21. Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K, Proper J, Weeden W, Miller TE, Chatis P, et al.: Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 2005, 23:982-989.
22. Zhu H, Cong JP, Mamtora G, Gingeras T, Shenk T: Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. Proc Natl Acad Sci USA 1998, 95:14470-14475.
23. Speir E, Yu Z-X, Ferrans VJ, Huang E-S, Epstein SE: Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circ Res 1998, 83:210-216.
24. Rue CA, Jarvis MA, Knoche AJ, Meyers HL, DeFilippis VP, Hansen SG, Wagner M, Fruh K, Anders DG, Wong SW, et al.: A cyclooxygenase-2 homologue encoded by rhesus cytomegalovirus is a determinant for endothelial cell tropism. J Virol 2004, 78:12529-12536.
25. Einav S, Glenn JS: Prenylation inhibitors: a novel class of antiviral agents. J Antimicrob Chemother 2003, 52:883-886.
26. van't Wout AB, Swain JV, Schindler M, Rao U, Pathmajeyan MS, Mullins JI, Kirchhoff F: Nef induces multiple genes involved in cholesterol synthesis and uptake in human immunodeficiency virus type I-infected T cells. J Virol 2005, 79:10053-10058.
27. van't Wout AB, Lehrman GK, Mikheeva SA, O'Keeffe GC, Katze MG, Bumgarner RE, Geiss GK, Mullins JI: Cellular gene expression upon human immunodeficiency virus type I infection of CD4(+)-T-cell lines. J Virol 2003, 77:1392-1402.
28. Lau A, Swinbank KM, Ahmed PS, Taylor DL, Jackson SP, Smith GC, O'Connor MJ: Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. Nat Cell Biol 2005, 7:493-500.
29. Hauber I, Bevec D, Heukeshoven J, Kratzer F, Horn F, Choidas A, Harrer T, Hauber J: Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy. J Clin Invest 2005, 115:76-85.
30. Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, Kaufman RJ, Ma D, Coen DM, Ron D, Yuan J: A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 2005, 307:935-939.
31. Ng LF, Chan M, Chan SH, Cheng PC, Leung EH, Chen WN, Ren EC: Host heterogeneous ribonucleoprotein K (hnRNP K) as a potential target to suppress hepatitis B virus replication. PLoS Med 2005, 2:e163.
32. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM: Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004, 18:1101-1108.
33. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW: Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005, 366:549-555.
34. Searls DB: Data integration: challenges for drug discovery. Nat Rev Drug Discov 2005, 4:45-58.
35. Kramer R, Cohen D: Functional genomics to new drug targets. Nat Rev Drug Discov 2004, 3:965-972.
36. Katze MG, He Y, Gale M Jr. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002, 2:675-687.
37. Kushner DB, Lindenbach BD, Grdzelishvili VZ, Noueiry AO, Paul SM, Ahlquist P: Systematic, genome-wide identification of host genes affecting replication of a positive-strand RNA virus. Proc Natl Acad Sci USA 2003, 100:15764-15769.
38. Panavas T, Serviene E, Brasher J, Nagy PD: Yeast genome-wide screen reveals dissimilar sets of host genes affecting replication of RNA viruses. Proc Natl Azad Sci USA 2005, 102:7326-7331.
39. Serviene E, Shapka N, Cheng CP, Panavas T, Phuangrat B, Baker J, Nagy PD: Genome-wide screen identifies host genes affecting viral RNA recombination. Proc Natl Acad Sci USA 2005, 102:10545-10550.
40. Silva JM, Mizuno H, Brady A, Lucito R, Hannon GJ: RNA interference microarrays: high-throughput loss-of-function genetics in mammalian cells. Proc Natl Acad Sci USA 2004, 101:6548-6552.
41. Berns K, Hijmans EM, Mullenders J, Brummelkamp TP, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, et al.: A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004, 428:431-437.
42. Dunn SJ, Khan IH, Chan UA, Scearce RL, Melara CL, Paul AM, Sharma V, Bih F-Y, Holzmayer TA, Luciw PA, Abo A: Identification of cell surface targets for HIV-1 therapeutics using genetic screens. Virology 2004, 321:260-273.